JP2002540221A - 海洋源からの精製されたトリグリセリドを、穏やかな安定性油に変換するプロセス - Google Patents
海洋源からの精製されたトリグリセリドを、穏やかな安定性油に変換するプロセスInfo
- Publication number
- JP2002540221A JP2002540221A JP2000596107A JP2000596107A JP2002540221A JP 2002540221 A JP2002540221 A JP 2002540221A JP 2000596107 A JP2000596107 A JP 2000596107A JP 2000596107 A JP2000596107 A JP 2000596107A JP 2002540221 A JP2002540221 A JP 2002540221A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- omega
- refined
- fatty acids
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003921 oil Substances 0.000 title claims abstract description 426
- 238000000034 method Methods 0.000 title claims abstract description 128
- 230000008569 process Effects 0.000 title claims description 74
- 150000003626 triacylglycerols Chemical class 0.000 title description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 82
- 239000004927 clay Substances 0.000 claims abstract description 52
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 33
- 238000004061 bleaching Methods 0.000 claims abstract description 26
- 239000000126 substance Substances 0.000 claims abstract description 26
- 241000251468 Actinopterygii Species 0.000 claims abstract description 22
- 238000004332 deodorization Methods 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 16
- 229910052751 metal Inorganic materials 0.000 claims abstract description 10
- 239000002184 metal Substances 0.000 claims abstract description 10
- 150000002739 metals Chemical class 0.000 claims abstract description 9
- 235000019198 oils Nutrition 0.000 claims description 421
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 76
- 241000283216 Phocidae Species 0.000 claims description 58
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 57
- 239000000796 flavoring agent Substances 0.000 claims description 47
- 235000019634 flavors Nutrition 0.000 claims description 47
- 235000013305 food Nutrition 0.000 claims description 39
- 239000006014 omega-3 oil Substances 0.000 claims description 37
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 35
- 239000010779 crude oil Substances 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 24
- 235000021588 free fatty acids Nutrition 0.000 claims description 23
- 239000000575 pesticide Substances 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 235000019688 fish Nutrition 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 235000021323 fish oil Nutrition 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 229910052742 iron Inorganic materials 0.000 claims description 17
- 235000004626 essential fatty acids Nutrition 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 16
- 229910002027 silica gel Inorganic materials 0.000 claims description 16
- 150000002978 peroxides Chemical class 0.000 claims description 14
- 238000007670 refining Methods 0.000 claims description 14
- 229910052802 copper Inorganic materials 0.000 claims description 13
- 239000010949 copper Substances 0.000 claims description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 239000011574 phosphorus Substances 0.000 claims description 11
- 229910052698 phosphorus Inorganic materials 0.000 claims description 11
- 241001529469 Phoca groenlandica Species 0.000 claims description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 241000283153 Cetacea Species 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 230000001877 deodorizing effect Effects 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 241000269821 Scombridae Species 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 235000011868 grain product Nutrition 0.000 claims description 6
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 6
- 235000020640 mackerel Nutrition 0.000 claims description 6
- 210000002741 palatine tonsil Anatomy 0.000 claims description 6
- 241000972773 Aulopiformes Species 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000019515 salmon Nutrition 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 235000008429 bread Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000283118 Halichoerus grypus Species 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 235000015142 cultured sour cream Nutrition 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 230000018109 developmental process Effects 0.000 claims description 3
- 235000013601 eggs Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 235000014438 salad dressings Nutrition 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 239000008256 whipped cream Substances 0.000 claims description 3
- 235000008939 whole milk Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 241000283125 Halichoerus Species 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 241000283150 Phoca vitulina Species 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 230000004641 brain development Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 230000009067 heart development Effects 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 230000034435 immune system development Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 239000002199 base oil Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 9
- 239000000344 soap Substances 0.000 abstract description 7
- 230000003244 pro-oxidative effect Effects 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 238000004040 coloring Methods 0.000 abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 229920000715 Mucilage Polymers 0.000 abstract description 4
- 239000000853 adhesive Substances 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000004065 wastewater treatment Methods 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000000968 medical method and process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 24
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 20
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 20
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 20
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 20
- 230000003647 oxidation Effects 0.000 description 20
- 238000007254 oxidation reaction Methods 0.000 description 20
- 238000001514 detection method Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000012545 processing Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229930003799 tocopherol Natural products 0.000 description 12
- 239000011732 tocopherol Substances 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 11
- 235000012239 silicon dioxide Nutrition 0.000 description 11
- 235000019645 odor Nutrition 0.000 description 10
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 10
- 239000008157 edible vegetable oil Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000001590 oxidative effect Effects 0.000 description 8
- 235000010384 tocopherol Nutrition 0.000 description 8
- 229960001295 tocopherol Drugs 0.000 description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 229910001873 dinitrogen Inorganic materials 0.000 description 7
- -1 lipid peroxide Chemical class 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 7
- 239000008158 vegetable oil Substances 0.000 description 7
- 238000009874 alkali refining Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 229940013317 fish oils Drugs 0.000 description 5
- 230000009965 odorless effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000021388 linseed oil Nutrition 0.000 description 4
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000019149 tocopherols Nutrition 0.000 description 4
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000010775 animal oil Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010016260 Fatty acid deficiency Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000006103 coloring component Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 102220229106 rs753340463 Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006220 Breast cyst Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001507939 Cormus domestica Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000631695 Homo sapiens Succinate dehydrogenase assembly factor 3, mitochondrial Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100028996 Succinate dehydrogenase assembly factor 3, mitochondrial Human genes 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000027720 dry mucous membrane Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009875 water degumming Methods 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/10—Refining fats or fatty oils by adsorption
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/16—Fatty acid esters
- A21D2/165—Triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Husbandry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,260,397 | 1999-01-29 | ||
| CA002260397A CA2260397A1 (en) | 1999-01-29 | 1999-01-29 | Method of converting rendered triglyceride oil from marine sources into bland, stable food oil |
| PCT/CA2000/000078 WO2000044862A1 (en) | 1999-01-29 | 2000-01-28 | Process of converting rendered triglyceride oil from marine sources into bland, stable oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002540221A true JP2002540221A (ja) | 2002-11-26 |
| JP2002540221A5 JP2002540221A5 (OSRAM) | 2007-04-19 |
Family
ID=4163238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596107A Pending JP2002540221A (ja) | 1999-01-29 | 2000-01-28 | 海洋源からの精製されたトリグリセリドを、穏やかな安定性油に変換するプロセス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7179491B1 (OSRAM) |
| EP (1) | EP1151067A1 (OSRAM) |
| JP (1) | JP2002540221A (OSRAM) |
| AU (1) | AU2273600A (OSRAM) |
| CA (1) | CA2260397A1 (OSRAM) |
| WO (1) | WO2000044862A1 (OSRAM) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002080887A (ja) * | 2000-09-04 | 2002-03-22 | Spirulina Biological Lab Ltd | ドコサペンタエン酸含有グリセリドの製造方法 |
| CN103881801A (zh) * | 2013-10-27 | 2014-06-25 | 刘跃 | 取消精炼工序并能有效降低食用油中水分的方法 |
| KR20160008200A (ko) * | 2013-04-22 | 2016-01-21 | 스마트피쉬 에이에스 | 암의 치료―후 처치 및／또는 치료를 위한 주스 및 생선 오일을 포함하는 조성물의 용도 |
| JP2021137035A (ja) * | 2015-12-21 | 2021-09-16 | 備前化成株式会社 | 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品 |
| JP2022510828A (ja) * | 2018-12-14 | 2022-01-28 | ディーエスエム アイピー アセッツ ビー．ブイ． | 向上された嗜好性を有する多価不飽和脂肪酸含有食品成分及びそれを製造する方法 |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
| CA2260397A1 (en) | 1999-01-29 | 2000-07-29 | Atlantis Marine Inc. | Method of converting rendered triglyceride oil from marine sources into bland, stable food oil |
| PT102509A (pt) * | 2000-08-16 | 2002-02-28 | Fundacao Essprit Icarus | Composicoes farmaceuticas, cosmeticas e dermo-cosmeticas, de higiene, alimentares e para-alimentares a base de oleo de foca, e sua utilizacao |
| WO2003003855A1 (de) * | 2001-07-05 | 2003-01-16 | Luedke Hans-Werner | Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen |
| EP1417211B1 (en) | 2001-07-27 | 2007-05-30 | Neptune Technologies & Bioressources Inc. | Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses |
| WO2003055323A1 (en) * | 2001-12-27 | 2003-07-10 | Genesis Group Inc. | Seal oil based lipid emulsions and uses thereof |
| EP2266525B1 (en) | 2002-05-03 | 2012-07-11 | Martek Biosciences Corporation | High quality lipids and methods for producing by enzymatic liberation from biomass |
| SE0202188D0 (sv) | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| EP2295529B2 (en) | 2002-07-11 | 2022-05-18 | Basf As | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
| WO2004028470A2 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| EP2384750A1 (en) * | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
| ATE430802T1 (de) | 2003-08-21 | 2009-05-15 | Monsanto Technology Llc | Fettsäuredesaturasen aus primula |
| WO2005023021A1 (ja) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | ダイエット食品 |
| ITMI20032247A1 (it) * | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | Interazione di derivati polari di composti insaturi con substrati inorganici |
| CN1968688A (zh) | 2004-04-16 | 2007-05-23 | 孟山都技术有限公司 | 脂肪酸去饱和酶在玉米中的表达 |
| DE602005021675D1 (de) * | 2004-11-04 | 2010-07-15 | Monsanto Technology Llc | Verfahren zur herstellung von ölzusammensetzungen |
| PE20070482A1 (es) | 2005-08-26 | 2007-06-08 | Ocean Nutrition Canada Ltd | Metodo para remover y/o reducir esteroles a partir de aceites |
| US7977498B2 (en) * | 2005-08-26 | 2011-07-12 | Ocean Nutrition Canada Limited | Reduction of sterols and other compounds from oils |
| US20070059340A1 (en) * | 2005-09-09 | 2007-03-15 | Anthony Bello | Omega-3 Fatty Acids Encapsulated In Zein Coatings and Food Products Incorporating the Same |
| US7867538B2 (en) | 2005-12-20 | 2011-01-11 | Archer Daniels Midland Company | Processes of improving the quality of oil and products produced therefrom |
| CN105475116A (zh) | 2006-03-10 | 2016-04-13 | 孟山都技术有限公司 | 大豆种子和油的组成以及产生所述种子的方法 |
| TW200820913A (en) * | 2006-08-25 | 2008-05-16 | Martek Biosciences Corp | Food fortification with polyunsaturated fatty acids |
| US20090162525A1 (en) * | 2007-12-21 | 2009-06-25 | Tropicana Products, Inc. | Food product including one or more encapsulated omega-3 fatty acids and one or more fruit flavors |
| WO2009102558A2 (en) * | 2008-02-11 | 2009-08-20 | Monsanto Technology Llc | Aquaculture feed, products, and methods comprising beneficial fatty acids |
| WO2009132463A1 (en) * | 2008-05-02 | 2009-11-05 | Neptune Technologies & Bioressources Inc. | New deodorization method and organoleptic improvement of marine oil extracts |
| WO2010049954A1 (en) | 2008-10-31 | 2010-05-06 | Lipid Pharmaceuticals Ehf. | Fatty acids for use as a medicament |
| DE102008060059A1 (de) * | 2008-12-02 | 2010-06-10 | Süd-Chemie AG | Verfahren zur Reduzierung des 3-MCPD-Gehalts in raffinierten Pflanzenölen |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| MX350088B (es) | 2009-04-29 | 2017-08-25 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| US9480271B2 (en) | 2009-09-15 | 2016-11-01 | Monsanto Technology Llc | Soybean seed and oil compositions and methods of making same |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| NO2493478T3 (OSRAM) | 2009-10-29 | 2018-07-21 | ||
| ES2618069T3 (es) | 2010-03-09 | 2017-06-20 | Stepan Specialty Products, Llc | Método para tratar un aceite comestible y el aceite obtenido de esta manera |
| KR101907411B1 (ko) | 2010-03-12 | 2018-10-12 | 베르그 엘엘씨 | 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법 |
| CA2801011C (en) | 2010-06-01 | 2019-02-26 | Dsm Ip Assests B.V. | Extraction of lipid from cells and products therefrom |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| CN107095863A (zh) | 2011-06-17 | 2017-08-29 | 博格有限责任公司 | 可吸入药物组合物 |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| CA3067012C (en) | 2012-06-29 | 2021-10-05 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US9637706B2 (en) * | 2012-07-31 | 2017-05-02 | Dsm Ip Assets B.V. | Refinement of oils using green tea extract antioxidants |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| TWI646189B (zh) | 2013-12-20 | 2019-01-01 | 荷蘭商Ｄｓｍ智慧財產有限公司 | 用於從微生物細胞獲得微生物油之方法（五） |
| NZ721417A (en) | 2013-12-20 | 2022-07-01 | Dsm Ip Assets Bv | Processes for obtaining microbial oil from microbial cells |
| AR098896A1 (es) | 2013-12-20 | 2016-06-22 | Dsm Ip Assets Bv | Proceso para obtener aceite microbiano a partir de células microbianas |
| CN106029624B (zh) | 2013-12-20 | 2021-12-07 | 帝斯曼知识产权资产管理有限公司 | 用于从微生物细胞获得微生物油的方法 |
| AU2014369045B2 (en) | 2013-12-20 | 2020-02-27 | Dsm Ip Assets B.V. | Processes for obtaining microbial oil from microbial cells |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| CN107746747A (zh) * | 2017-11-08 | 2018-03-02 | 厦门汇盛生物有限公司 | 一种降低多不饱和脂肪酸油过氧化值和茴香胺值的方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| US20240081374A1 (en) * | 2022-09-14 | 2024-03-14 | Société des Produits Nestlé S.A. | Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal |
| WO2025145410A1 (en) * | 2024-01-05 | 2025-07-10 | Cargill, Incorporated | Methods of refining liquid oil and controlling p-anisidine value |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5284206A (en) * | 1975-11-13 | 1977-07-13 | Unilever Nv | Method of purifying crude glyceride oil composition |
| JPH03203998A (ja) * | 1989-03-21 | 1991-09-05 | Unilever Nv | シリカヒドロゲルを用いるグリセリド油の精製方法 |
| JPH0633086A (ja) * | 1992-05-05 | 1994-02-08 | Wr Grace & Co Connecticut | 吸着法により油脂材料から硫黄化合物を除去する方法 |
| JPH06181725A (ja) * | 1992-12-17 | 1994-07-05 | Kiteii:Kk | 易酸化性油状物の固形化剤 |
| JPH07501355A (ja) * | 1991-11-15 | 1995-02-09 | エフ・ホフマン−ラ ロシユ アーゲー | 海産油の安定化 |
| JPH07203845A (ja) * | 1994-01-14 | 1995-08-08 | Nippon Synthetic Chem Ind Co Ltd:The | 油脂の味覚改良方法 |
| JPH0853692A (ja) * | 1994-05-09 | 1996-02-27 | Soc Prod Nestle Sa | ポリ不飽和脂肪酸エステル濃縮物の製造方法 |
| JPH1161176A (ja) * | 1997-08-11 | 1999-03-05 | Nogyo Kyodo Kumiai Chuokai | 蜜蝋の製造方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58194994A (ja) | 1982-05-10 | 1983-11-14 | リノ−ル油脂株式会社 | 粗製グリセリド油組成物の精製方法 |
| JPS59176264A (ja) | 1983-03-04 | 1984-10-05 | Itochu Shiryo Kk | 生理活性物質 |
| JPS6023493A (ja) | 1983-07-18 | 1985-02-06 | 高尾 正保 | 精製魚油の製法 |
| US4880574A (en) | 1984-12-07 | 1989-11-14 | W. R. Grace & Co.-Conn. | Method for refining glyceride oils using partially dried amorphous silica hydrogels |
| US4734226A (en) | 1986-01-28 | 1988-03-29 | W. R. Grace & Co. | Method for refining glyceride oils using acid-treated amorphous silica |
| US4629588A (en) | 1984-12-07 | 1986-12-16 | W. R. Grace & Co. | Method for refining glyceride oils using amorphous silica |
| US4678808A (en) * | 1985-10-15 | 1987-07-07 | Baxter Travenol Laboratories, Inc. | Rapid acting intravenous emulsions of omega-3 fatty acid esters |
| JPS6293234A (ja) | 1985-10-21 | 1987-04-28 | Terumo Corp | 精製された魚油およびその製造方法 |
| US5336794A (en) * | 1986-05-14 | 1994-08-09 | W. R. Grace & Co.-Conn. | Dual phase adsorption and treatment of glyceride oils |
| DE3775008D1 (de) | 1986-11-24 | 1992-01-16 | Unilever Nv | Metall-oxid-siliziumdioxid enthaltendes sorbentmittel und dessen verwendung zur oelraffinierung. |
| DE3643848A1 (de) | 1986-12-22 | 1988-09-01 | Natec Inst Naturwiss | Verfahren zur herstellung hochraffinierter essbarer glyceridoele mit einem anteil an ungesaettigten fettsaeuren im triglyceridverband und ihre verwendung |
| IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
| US4780309A (en) * | 1987-06-16 | 1988-10-25 | Warner-Lambert Company | Edible aerosol foam compositions and method of preparing same |
| US4874629A (en) | 1988-05-02 | 1989-10-17 | Chang Stephen S | Purification of fish oil |
| US5264597A (en) | 1988-09-30 | 1993-11-23 | Van Den Bergh Foods, Co., Division Of Conopco, Inc. | Process for refining glyceride oil using precipitated silica |
| US5012761A (en) | 1988-11-17 | 1991-05-07 | Oh Suk Y | Chicken egg having relatively high percentage of long chain fatty acids and method of reducing heart related disease in humans using such eggs |
| US5079208A (en) | 1988-12-30 | 1992-01-07 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Synthetic, macroporous, amorphous alumina silica and a process for refining glyceride oil |
| US5053169A (en) | 1989-08-08 | 1991-10-01 | W. R. Grace & Co.-Conn. | Method for refining wax esters using amorphous silica |
| US5149851A (en) | 1990-10-25 | 1992-09-22 | The United States Of America As Represented By The Secretary Of Commerce | Process for preparing triglycerides containing polyunsaturated fatty acid moieties |
| US5855944A (en) * | 1991-11-15 | 1999-01-05 | Roche Vitamins Inc. | Stabilization of marine oils |
| JPH06116585A (ja) | 1992-10-09 | 1994-04-26 | Kanegafuchi Chem Ind Co Ltd | 油脂の精製方法 |
| US5693835A (en) | 1994-01-27 | 1997-12-02 | Snow Brand Milk Products Co., Ltd. | Fish oil having decreased fish odor and a method for preparing the same |
| US5720980A (en) | 1994-02-23 | 1998-02-24 | Bar-Kan University | Plant protection using fish oil |
| WO1996028150A1 (en) | 1995-02-20 | 1996-09-19 | Marit Eriksen | Therapeutic skin cream |
| JP2815562B2 (ja) | 1995-11-13 | 1998-10-27 | 植田製油株式会社 | 高度不飽和脂肪酸含有油脂の精製方法 |
| CA2260397A1 (en) | 1999-01-29 | 2000-07-29 | Atlantis Marine Inc. | Method of converting rendered triglyceride oil from marine sources into bland, stable food oil |
-
1999
- 1999-01-29 CA CA002260397A patent/CA2260397A1/en not_active Abandoned
-
2000
- 2000-01-28 AU AU22736/00A patent/AU2273600A/en not_active Abandoned
- 2000-01-28 JP JP2000596107A patent/JP2002540221A/ja active Pending
- 2000-01-28 WO PCT/CA2000/000078 patent/WO2000044862A1/en not_active Ceased
- 2000-01-28 EP EP00901447A patent/EP1151067A1/en not_active Withdrawn
- 2000-01-28 US US09/890,383 patent/US7179491B1/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5284206A (en) * | 1975-11-13 | 1977-07-13 | Unilever Nv | Method of purifying crude glyceride oil composition |
| JPH03203998A (ja) * | 1989-03-21 | 1991-09-05 | Unilever Nv | シリカヒドロゲルを用いるグリセリド油の精製方法 |
| JPH07501355A (ja) * | 1991-11-15 | 1995-02-09 | エフ・ホフマン−ラ ロシユ アーゲー | 海産油の安定化 |
| JPH0633086A (ja) * | 1992-05-05 | 1994-02-08 | Wr Grace & Co Connecticut | 吸着法により油脂材料から硫黄化合物を除去する方法 |
| JPH06181725A (ja) * | 1992-12-17 | 1994-07-05 | Kiteii:Kk | 易酸化性油状物の固形化剤 |
| JPH07203845A (ja) * | 1994-01-14 | 1995-08-08 | Nippon Synthetic Chem Ind Co Ltd:The | 油脂の味覚改良方法 |
| JPH0853692A (ja) * | 1994-05-09 | 1996-02-27 | Soc Prod Nestle Sa | ポリ不飽和脂肪酸エステル濃縮物の製造方法 |
| JPH1161176A (ja) * | 1997-08-11 | 1999-03-05 | Nogyo Kyodo Kumiai Chuokai | 蜜蝋の製造方法 |
Non-Patent Citations (2)
| Title |
|---|
| E VOGNID, LIPIDS, vol. 33, no. 4, JPN5001024567, 1998, US, pages 427 - 436, ISSN: 0001701988 * |
| U N WANASUNDARA, FOOD CHEMISTRY, vol. 63, no. 3, JPN5001024568, 1998, GB, pages 335 - 342, ISSN: 0001701987 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002080887A (ja) * | 2000-09-04 | 2002-03-22 | Spirulina Biological Lab Ltd | ドコサペンタエン酸含有グリセリドの製造方法 |
| KR20160008200A (ko) * | 2013-04-22 | 2016-01-21 | 스마트피쉬 에이에스 | 암의 치료―후 처치 및／또는 치료를 위한 주스 및 생선 오일을 포함하는 조성물의 용도 |
| KR102253929B1 (ko) | 2013-04-22 | 2021-05-20 | 스마트피쉬 에이에스 | 암의 치료―후 처치 및／또는 치료를 위한 주스 및 생선 오일을 포함하는 조성물의 용도 |
| CN103881801A (zh) * | 2013-10-27 | 2014-06-25 | 刘跃 | 取消精炼工序并能有效降低食用油中水分的方法 |
| JP2021137035A (ja) * | 2015-12-21 | 2021-09-16 | 備前化成株式会社 | 高度不飽和脂肪酸含有組成物及び該組成物を含有する食品 |
| JP7129723B2 (ja) | 2015-12-21 | 2022-09-02 | 備前化成株式会社 | 高度不飽和脂肪酸のトリグリセリドを含む組成物 |
| JP2022510828A (ja) * | 2018-12-14 | 2022-01-28 | ディーエスエム アイピー アセッツ ビー．ブイ． | 向上された嗜好性を有する多価不飽和脂肪酸含有食品成分及びそれを製造する方法 |
| JP7550755B2 (ja) | 2018-12-14 | 2024-09-13 | ディーエスエム アイピー アセッツ ビー．ブイ． | 向上された嗜好性を有する多価不飽和脂肪酸含有食品成分及びそれを製造する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7179491B1 (en) | 2007-02-20 |
| EP1151067A1 (en) | 2001-11-07 |
| WO2000044862A1 (en) | 2000-08-03 |
| AU2273600A (en) | 2000-08-18 |
| CA2260397A1 (en) | 2000-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7179491B1 (en) | Process of converting rendered triglyceride oil from marine sources into bland, stable oil | |
| CA2694054C (en) | Omega-3 fatty acid fortified composition | |
| JP2002540221A5 (OSRAM) | ||
| CN1871331B (zh) | 对多不饱和脂肪酸(pufa)酯浓缩物的稳定方法 | |
| US9273267B2 (en) | Method of treating an edible oil | |
| JP2014128273A (ja) | 海産物油の脱臭および安定化 | |
| JPH0424979B2 (OSRAM) | ||
| JP2000104092A (ja) | 血清脂質改善油脂組成物 | |
| JP6896417B2 (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
| MEYER et al. | Fate of the synergistic antioxidant system ascorbic acid, lecithin, and tocopherol in mayonnaise: partition of ascorbic acid | |
| JP2001346517A (ja) | 食用油脂。 | |
| CA2346407C (en) | Process of converting rendered triglyceride oil from marine sources into bland, stable oil | |
| JPH0336493B2 (OSRAM) | ||
| AU2017323114B2 (en) | Fish odor-free fish oil composition and preparation method therefor | |
| JP3061777B2 (ja) | 卵黄レシチン混合物 | |
| JPH02203741A (ja) | 高度不飽和脂肪酸含有マーガリン | |
| JPH08259988A (ja) | 酸化防止剤及びこれを用いた油脂の酸化防止方法 | |
| Shahidi et al. | Seal blubber oil: a novel source of ω3 fatty acids | |
| JP5916505B2 (ja) | ω３系列高度不飽和脂肪酸含有味付け海苔の製造方法 | |
| RU2242138C1 (ru) | Пищевой эмульсионный жировой продукт | |
| JP2521155B2 (ja) | 可塑性油脂組成物 | |
| JP3352578B2 (ja) | 安定な油脂、その製造法及びそれを配合した飲食品 | |
| JPH02292397A (ja) | 食用油脂組成物及び加工食品 | |
| JPH0276558A (ja) | α−リノレン酸強化魚肉ソーセージ | |
| JP2000239168A (ja) | 脳卒中予防剤およびこれを配合してなる組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110418 |